by SWK Holdings | Feb 21, 2019 | Case Study
In December 2012 SWK acquired a limited partnership interest in Holmdel Pharmaceuticals Holmdel subsequently acquired the U.S. marketing authorization rights to InnoPran XL, a non-selective beta blocker using dosing technology to provide maximum active ingredient...
by SWK Holdings | Feb 21, 2019 | Case Study
Narcan is the only FDA approved, intranasal Naloxone product for the treatment of opioid overdose Narcan is appropriately priced with revenue growth due to a differentiated nasal dosing and expanded distribution, not price hikes Opiant is a publicly traded drug...
by SWK Holdings | Feb 21, 2019 | Case Study
Orametrix was a Dallas-based, digital orthodontic company providing robotically bent and highly-accurate wire arches for braces In late 2016 the company approached SWK in need of funding to expand into the clear aligner market Upon completion of this project,...
